Dr Bruce Booth

Dr Bruce Booth is a Partner in the life sciences group of Atlas Venture, Inc., an early stage venture capital firm, where he focuses on identifying and funding the development of new therapeutics, medical devices, and diagnostic technologies aimed at addressing major unmet medical needs. Dr Booth currently serves on the Boards and was a founding investor of Atlas portfolio companies Avila Therapeutics, Miragen Therapeutics, and Zafgen Inc. He has also invested in or has worked closely with ARCA Biopharma, Archemix, Prestwick Pharmaceuticals (sold to Biovail), Proprius Pharmaceuticals (sold to Cypress Biosciences), and Stromedix. Before joining Atlas in 2005, Dr Booth was a Principal at Caxton Health Holdings, a healthcare-focused investment ﬁrm, where he helped lead the ﬁrm's private equity activities, ranging from early stage venture capital through late stage private equity. Prior to Caxton, he was a consultant at McKinsey & Company, where he advised biopharmaceutical clients on R&D productivity, corporate strategy, and business development issues.

He earned a Doctorate in Molecular Immunology from the Oxford University's Nufﬁeld Department of Medicine and the Weatherall Institute of Molecular Medicine as a British Marshall Scholar. His research focused on immune surveillance, and how the immune system responds to intracellular pathogenesis. He received his Bachelor of Science degree summa cum laude in Biochemistry from the Pennsylvania State University.

Dr Booth is a Trustee of the New York Academy of Medicine and has been a member of the Council on Foreign Relations. He currently serves in several life science advisory roles, including the Beth Israel Deaconess Medical Center's Accelerating Bench to Bedside effort and LifeTech Boston seed-stage loan programme, and has been a reviewer for NIH SBIR grants with the NCI and NHLBI. He has also authored numerous scientiﬁc papers and biotech venture capital review articles, including several in Nature Biotechnology and Nature Reviews Drug Discovery.